Sonoma Pharmaceuticals, Inc. Cash Flow Statement
SNOA|15 years of annual SEC 10-K data (FY2011-FY2026)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Sonoma Pharmaceuticals, Inc. used $88,000 in operating cash flow and negative free cash flow of $168,000 in FY2026.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$3.5M | -$4.8M | -$5.2M | -$5.1M | -$4.0M | -$3.3M | -$11.8M | -$14.3M | $9.3M | -$10.2M | -$8.2M | $3.7M | -$5.4M | -$7.3M | -$7.9M |
| Depreciation & Amortization | $138.0K | $176.0K | $125.0K | $186.0K | $227.0K | $312.0K | $453.0K | $490.0K | $248.0K | $244.0K | $253.0K | $284.0K | $268.0K | $326.0K | $395.0K |
| Operating Cash Flow | -$88.0K | -$2.4M | -$6.2M | -$4.2M | -$3.4M | -$4.6M | -$11.7M | -$12.4M | -$8.2M | -$8.7M | -$6.7M | -$4.9M | $1.1M | -$4.0M | -$4.4M |
| Capital Expenditures | $80.0K | $2.0K | $269.0K | $137.0K | $179.0K | $206.0K | $100.0K | $187.0K | $394.0K | $345.0K | $139.0K | $504.0K | $257.0K | $336.0K | $174.0K |
| Free Cash Flow | -$168.0K | -$2.4M | -$6.4M | -$4.4M | -$3.6M | -$4.8M | -$11.8M | -$12.6M | -$8.6M | -$9.1M | -$6.8M | -$5.4M | $893.0K | -$4.4M | -$4.6M |
| FCF Margin | -1.2% | -18.9% | -48.4% | -34.7% | -19.1% | -26.8% | -62.3% | -75.8% | -66.8% | -97.0% | -49.3% | -39.5% | 5.8% | -34.3% | -47.2% |